Clinical Trials Logo

Clinical Trial Summary

CelAgace™ OraRinse (silver citrate complex and acemannan) Solution is planned to be evaluated for safety and effectiveness as a potential treatment for candidiasis, a yeast infection, commonly known as thrush, which is associated with mouth sores.


Clinical Trial Description

CelAgace™ contains two active ingredients, a silver citrate complex salt (0.01mg/ml) that has demonstrated laboratory effectiveness against yeast organisms and acemannan (4.0mg/ml), a purified extract isolated from the inner leaf gel of the Aloe vera plant that has been used as a key ingredient in other oral care products. Patients will swish and spit the product 4 times daily (after meals and at bedtime) for 14 days. Following an initial office visit, patients will be evaluated on days 7 and 14 to determine response to the product. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03250923
Study type Interventional
Source CelaCare Technologies, Inc.
Contact Jacqueline M. Plemons, DDS, MS
Phone 214-828-8467
Email jplemons@tamhsc.edu
Status Not yet recruiting
Phase Phase 1/Phase 2
Start date September 2024
Completion date May 2025

See also
  Status Clinical Trial Phase
Completed NCT00004781 - Oral Manifestations of Human Immunodeficiency Virus Infection in High Risk Groups N/A
Completed NCT03894839 - Evaluation of the Effect of Different Cleaning and Disinfection Procedures on the Involvement of Candida Species N/A
Completed NCT00128323 - A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating Oropharyngeal Candidiasis Phase 3
Recruiting NCT04410250 - Effect of Oral Hygienization in Newborn on Candida Spp Colonization N/A
Completed NCT02184351 - Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis Phase 3
Recruiting NCT03873753 - Relationship Between Oral Hygiene in Newborns and Candida Spp. N/A
Completed NCT00665639 - Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis Phase 3
Completed NCT02818803 - Efficacy of Standardized-propolis Extract (EPP-AF®) Gel Formulation as Buccal Antiseptic Phase 3
Active, not recruiting NCT06120816 - Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis Phase 1
Completed NCT00235053 - Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 mcg BID Phase 4
Completed NCT00666185 - Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis Phase 3
Completed NCT00002446 - Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients Phase 3
Completed NCT00001448 - The Effect of Oral Candidiasis on the Speech Production, Feeding Skills, and Self-Concept of Children and Adolescents With Symptomatic HIV Infection N/A
Completed NCT00612963 - Novel Rinse to Treat in Oral Candidiasis in Cancer Patients N/A
Completed NCT00001812 - A Randomized, Double-Blind, Placebo Controlled Trial Evaluating the Impact of Nystatin on the Development of Oral Irritation in Patients Receiving High Dose Intravenous Interleukin-2 Phase 3
Completed NCT00001065 - A Study of Amphotericin B in the Treatment of Fungal Infections of the Mouth in HIV-Infected Patients Who Have Not Had Success With Fluconazole Phase 2
Completed NCT00000951 - A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush Phase 4
Completed NCT00002431 - The Safety and Effectiveness of Peridex in Preventing or Delaying Fungal Infections of the Mouth in HIV-Infected Patients N/A
Completed NCT00002341 - A Study of Treatments for Fungal Infections of the Mouth and Throat in HIV-Infected Patients Who Have Had Success With Itraconazole But Not With Fluconazole N/A
Completed NCT00002133 - An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory Oropharyngeal Candidiasis in HIV-Positive Subjects. N/A